The Division of Cancer Treatment & Diagnosis (DCTD), National Cancer Institute is actively exploring drug molecular mechanisms in conjunction with tumor gene expression, mutation and protein profiling to pair the development of newer anticancer agents with specific molecular vulnerabilities in the precision oncology medicine setting. The Leidos Biomedical program in molecular pharmacology at the Frederick [...]